87 related articles for article (PubMed ID: 9148861)
41. Prohibitin: targeting peptide coupled to ovarian cancer, luteinization and TGF-β pathways.
El-Etreby NM; Ghazy AA; Rashad R
J Ovarian Res; 2017 Apr; 10(1):28. PubMed ID: 28427435
[TBL] [Abstract][Full Text] [Related]
42. Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF-β signaling pathway.
Wang X; Gui L; Zhang Y; Zhang J; Shi J; Xu G
Int J Oncol; 2014 Apr; 44(4):1099-106. PubMed ID: 24452274
[TBL] [Abstract][Full Text] [Related]
43. Transforming growth factor-beta isoform expression in human ovarian tumours.
Bartlett JM; Langdon SP; Scott WN; Love SB; Miller EP; Katsaros D; Smyth JF; Miller WR
Eur J Cancer; 1997 Dec; 33(14):2397-403. PubMed ID: 9616289
[TBL] [Abstract][Full Text] [Related]
44. Expression and significance of transforming growth factor-β1 in epithelial ovarian cancer and its extracellular matrix.
Chen K; Wei H; Ling S; Yi C
Oncol Lett; 2014 Nov; 8(5):2171-2174. PubMed ID: 25295105
[TBL] [Abstract][Full Text] [Related]
45. Restoration of an impaired TGF-beta1 autocrine growth-inhibitory circuit results in growth inhibition of ovarian epithelial cancer cells and complete inhibition of their tumorigenicity.
Zeinoun Z; Teugels E; Vermeij J; Neyns B; Birrer M; De Grève J
Cancer Detect Prev; 2003; 27(5):380-8. PubMed ID: 14585325
[TBL] [Abstract][Full Text] [Related]
46. Quantitation of TGF-beta1 mRNA in porcine mesangial cells by comparative kinetic RT/PCR: comparison with ribonuclease protection assay and in situ hybridization.
Ceol M; Forino M; Gambaro G; Sauer U; Schleicher ED; D'Angelo A; Anglani F
J Clin Lab Anal; 2001; 15(4):215-22. PubMed ID: 11436205
[TBL] [Abstract][Full Text] [Related]
47. Epithelial-mesenchymal transformation of a newly established cell line from ovarian adenosarcoma by transforming growth factor-beta1.
Kitagawa K; Murata A; Matsuura N; Tohya K; Takaichi S; Monden M; Inoue M
Int J Cancer; 1996 Mar; 66(1):91-7. PubMed ID: 8608973
[TBL] [Abstract][Full Text] [Related]
48. Transforming growth factor-beta mRNA expression and growth control of human ovarian carcinoma cells.
Bartlett JM; Rabiasz GJ; Scott WN; Langdon SP; Smyth JF; Miller WR
Br J Cancer; 1992 May; 65(5):655-60. PubMed ID: 1586592
[TBL] [Abstract][Full Text] [Related]
49. Advances in reverse transcription polymerase chain reaction analysis of cellular mRNA levels of transforming growth factor-beta1 by capillary electrophoresis with laser-induced fluorescence detection.
Beck A; Lehmann R; Gambaro G; Häring HU; Schleicher ED; Voelter W; Ceol M
Clin Chem Lab Med; 1999 May; 37(5):527-32. PubMed ID: 10418743
[TBL] [Abstract][Full Text] [Related]
50. Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours.
Wilson KE; Langdon SP; Lessells AM; Miller WR
Br J Cancer; 1996 Oct; 74(7):999-1004. PubMed ID: 8855965
[TBL] [Abstract][Full Text] [Related]
51. Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mullerian tumors.
Kacinski BM; Carter D; Kohorn EI; Mittal K; Bloodgood RS; Donahue J; Kramer CA; Fischer D; Edwards R; Chambers SK
Yale J Biol Med; 1989; 62(4):379-92. PubMed ID: 2556864
[TBL] [Abstract][Full Text] [Related]
52. Loss of Drop1 expression already at early tumor stages in a wide range of human carcinomas.
Marmé A; Zimmermann HP; Moldenhauer G; Schorpp-Kistner M; Müller C; Keberlein O; Giersch A; Kretschmer J; Seib B; Spiess E; Hunziker A; Merchán F; Möller P; Hahn U; Kurek R; Marmé F; Bastert G; Wallwiener D; Ponstingl H
Int J Cancer; 2008 Nov; 123(9):2048-56. PubMed ID: 18709643
[TBL] [Abstract][Full Text] [Related]
53. SNP detection in transforming growth factor-beta1 gene using bacterial magnetic particles.
Ota H; Takeyama H; Nakayama H; Katoh T; Matsunaga T
Biosens Bioelectron; 2003 May; 18(5-6):683-7. PubMed ID: 12706579
[TBL] [Abstract][Full Text] [Related]
54. Transforming growth factor-beta (TGF-beta) in human milk.
Saito S; Yoshida M; Ichijo M; Ishizaka S; Tsujii T
Clin Exp Immunol; 1993 Oct; 94(1):220-4. PubMed ID: 8403511
[TBL] [Abstract][Full Text] [Related]
55. [A study of the expression of MDR1 gene in solid tumors. Initial results of a multicenter evaluation].
Chevillard S; Vielh P; Vallidire P; Robert J; Marie JP
Bull Cancer; 1996 Aug; 83(8):626-33. PubMed ID: 8869042
[TBL] [Abstract][Full Text] [Related]
56. Distinct tumor specific expression of TGFB4 (ebaf)*, a novel human gene of the TGF-beta superfamily.
Tabibzadeh S; Kothapalli R; Buyuksal I
Front Biosci; 1997 Jul; 2():a18-25. PubMed ID: 9230066
[TBL] [Abstract][Full Text] [Related]
57. Origins of heterogeneous ovarian carcinomas. A molecular cytogenetic analysis of histologically benign, low malignant potential, and fully malignant components.
Wolf NG; Abdul-Karim FW; Schork NJ; Schwartz S
Am J Pathol; 1996 Aug; 149(2):511-20. PubMed ID: 8701990
[TBL] [Abstract][Full Text] [Related]
58. Transforming growth factor-beta1 in hemangioma of the ovary.
Loverro G; Cormio G; Perlino E; Vicino M; Cazzolla A; Selvaggi L
Gynecol Obstet Invest; 1998; 46(3):210-3. PubMed ID: 9736807
[TBL] [Abstract][Full Text] [Related]
59. Analysis of molecular aberrations in ovarian cancer allows novel target identification.
Cheng KW; Lahad JP; Mills GB
J Obstet Gynaecol Can; 2004 May; 26(5):461-74. PubMed ID: 15151733
[TBL] [Abstract][Full Text] [Related]
60. Will molecular biology provide oncologists with information useful for risk assessment, prognosis, or therapeutic decisions in cancer patients?
Head JF
Cancer Invest; 1996; 14(6):635-6. PubMed ID: 8951366
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
